• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Home

Pulmonary Hypertension Team

Pulmonary Hypertension

Pulmonary Hypertension RN is an educational resource for patients, caregivers, friends, and family members interested in learning about PAH.   It is an exciting time for the pulmonary hypertension community because new pathways to treat the disease and new treatments are being researched and approved by the FDA (Food and Drug Administration).  Prior to 1996, there were no specific therapies approved to treat PAH.   Without treatment many pulmonary hypertension patients experienced rapid progression of their disease and eventually death.  Since then, the FDA has approved several treatments to slow down the progression of the disease and improve quality of life.  Unfortunately, due to a lack of awareness about PAH patients continue to be misdiagnosed or not treated. 

Jeremy Feldman, MD has devoted his career to treating patients with pulmonary arterial hypertension and has developed this resource to help educate the community and provide the most up to date information on treating pulmonary arterial hypertension.

This site provides information on:

  • Pulmonary arterial hypertension definition
  • Symptoms of pulmonary hypertension
  • Causes of pulmonary hypertension
  • Pulmonary arterial  hypertension diagnosis
  • Treatment for pulmonary hypertension
  • Chronic thromboembolic pulmonary hypertension

All information is edited by an MD and RN (Registered Nurse) specializing in pulmonary hypertension.

Latest from Our Blog

In Memoriam:  Greg Ahearn, MD

By Dr. Jeremy Feldman

The pulmonary hypertension community lost a Giant today.   I met Dr. Ahearn in the end of 2003.  He was leaving Duke where he had trained and was working as an attending physician on the pulmonary hypertension team.  He and I were moving to Phoenix to join a small pulmonary group named Arizona Pulmonary Specialists.  We started in the first […]

Sotatercept (Winrevair) Approved!

By Dr. Jeremy Feldman

On March 26, 2024 the FDA approved sotatercept (brand name of Winrevair), the first new class of medication approved in over a decade.  This medication acts by inhibiting signaling in the Activin pathway.  A major problem that contributes to PAH for most patients is impaired signaling in the BMPR pathway.  You can think of this signaling process as […]

generic medication

Disappointing News for Rodatristat Ethyl

By Dr. Jeremy Feldman

In July 2023, Enzyvant, now Sumitomo Pharma America, a subsidiary of Sumitomo Pharma, announced an update on their Phase 2 ELEVATE 2 study of Rodatristat Ethyl for PAH. The Phase 2b study failed to lower pulmonary vascular resistance, as measured by right heart catheterization, at Week 24. Sumitomo undertook a very rigorous evaluation of Rodatristat Ethyl […]

stimulant drugs associated with pulmonary arterial hypertension

Sotatercept Coming Soon

By Dr. Jeremy Feldman

An exciting new medication is expected to be approved in the next 12 months

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

Internal anatomy of the pulmonary arteries

Diastolic Heart Failure vs. PAH

By Dr. Jeremy Feldman

The most common disease confused with pulmonary arterial hypertension is diastolic heart failure (also called heart

Uptravi (Selexipag) for PAH

By Dr. Jeremy Feldman

Uptravi was approved in 2016 to treat Pulmonary Arterial Hypertension, PAH.  We now have more than four years

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives